Introduction
============

Several observational studies have demonstrated superior survival of patients with stage IV colorectal cancer (CRC) who undergo surgical resection of the primary tumor \[SRPT\] [@B1]-[@B6]. For example, a systematic review and meta-analysis of 15 observational studies involving 12456 patients with stage IV CRC demonstrated a hazard ratio (HR) for mortality of 0.69 (95% confidence interval \[CI\]: 0.61-0.79) favoring surgery [@B2]. A subsequent meta-analysis involving 44,226 patients in 21 studies indicated potential benefit of resection of the primary tumor in patients with unresectable metastases (odd ratio of 0.28; 95 % CI: 0.17-0.47), translating into a difference in mean survival of 6.4 months in favor of resection [@B3]. Yet the results are not confirmed in the setting of a randomized controlled trial. Lack of randomization and failure to control prognostic variables that affect survival including systemic therapy and performance status are major critiques to the findings of the observational studies. Consequently the survival benefit related to SRPT has been attributed to selection bias and selection of younger and healthier patients with good performance status.

Our group has demonstrated that surgical resection of the primary tumor improves survival of a cohort of patients with stage IV CRC, who were diagnosed between 1992-2005, irrespective of age, comorbid illness, performance status, chemotherapy, metastasectomy and other important prognostic variables [@B1]. In this group of patients SRPT was associated with 46% reduction in mortality (HR 0.54, 95%CI: 0.41-0.58). However, only 42% of patients were treated with systemic therapy. Among the treated patients about 45% received irinotecan or oxaliplatin based (FOLFIRI or FOLFOX) chemotherapy. Moreover, less than 5% patients received a biological agent. It is not known if similar benefit can be achieved with the use of more effective chemotherapy and biological agents in the management of metastatic CRC. We have undertaken the current study to confirm our findings in a cohort of patients with stage IV CRC who were diagnosed during the period of modern systemic therapy.

Objectives
==========

The study objectives were to validate prognostic impact of SRPT in patients with stage IV CRC who were treated with modern systemic therapy and to assess interaction of SRPT with other prognostic variables in order to identify subgroups of patients who received greater benefit from surgery.

Methods
=======

Eligibility Criteria
--------------------

The study protocol was approved by the University of Saskatchewan\'s Ethics Board. Individual records of patients ≥18 years, diagnosed with synchronous stage IV CRC between 2006 and 2010 in the province of Saskatchewan were reviewed. Patients with previous history of CRC, with another active second primary cancer, or who had pathology other than adenocarcinoma were excluded.

Statistical Analysis
--------------------

The primary end point of this study was to determine relationship between SRPT and overall survival (OS). Survival was estimated by using the Kaplan-Meier method. Survival distribution of subgroups was compared by the Log Rank test.

Charlson comorbidity index was used in this confirmatory study to defined major comorbid illness [@B7]. A multivariate analysis was performed to determine the prognostic significance of SRPT in patients with stage IV CRC in relation to other clinico-pathological variables. The Cox proportional hazard model was used and the hazard ratio (HR) and its 95% CI were estimated. Following variables were examined with respect to their prognostic significance:

Interventions: Resection of primary tumor, metastasectomy, use of chemotherapy with or without biologics , second line therapy, third line therapy, and radiation therapy; clinical & demographic variables: age (\<65 vs. ≥65), gender, major comorbid illness (as per Charlson comorbidity index), secondary cancer, Eastern Cooperative Oncology Group performance status \[ECOG PS\] (\<2 vs. ≥2), cancer center, and smoking; laboratory values: albumin (≥36 vs. \<36 g/l), bilirubin (≥26 vs. \<26 um/l), alkaline phosphatase (≥120 vs. \<120 U/l), sodium level (≤135 mEq/l vs. \>135 mEq/l), serum creatinine (≥120 vs. \<120 um/l), blood urea nitrogen (BUN) (≥8 vs. \<8 mm/l), hemoglobin (≥120 vs. \<120 g/l), white blood cell (WBC) (≥11 vs. \<11 x 10^9^/l), platelet count (≥450 vs. \<450 x10^9^/l), and carcinoembryonic antigen (CEA) (≥6 vs. \<6 ug/l); disease characteristics: site (colon vs. rectal), grade (3 vs. \<3), symptomatic disease, extra-hepatic metastases, and stage (stage IVa vs. stage IVb disease). For the Cox proportional hazard model, log-log survival curves were used to assess the proportional hazards assumption.

All variables that were significant on univariate analysis with P\<0.05, were examined in multivariate models. The likelihood ratio test and*t* test were used to determine if a variable correlates with survival in the model. Test for interaction was performed for SRPT and the other variables that were correlated with survival. In addition, secondary analyses were performed in subgroups of patients with asymptomatic disease, or patients who did not have metastasectomy. A two-sided P-value of \<0.05 was considered to be statistically significant. For missing data imputation technique was used. All patients were followed till June 2014 when the data entry was closed. The SPSS version 22 was used for statistical analysis (SPSS Inc. Chicago, IL).

Results
=======

Baseline Characteristics
------------------------

Five hundred and sixty-nine eligible patients with synchronous stage IV CRC were identified (**Figure [1](#F1){ref-type="fig"}**). Their median age was 69 years (range: 59-95) and male: female was 1.4:1. Three hundred and thirteen (55%) patients underwent surgery and 256 (45%) did not have surgery. Of 569 patients, 340 (60%) were ≥65 years and 201 (35%) had ECOG PS of ≥2 (**Table [1](#T1){ref-type="table"}**). Although no significant differences were noted between the two groups with respect to age, gender, comorbid illness, and smoking status, 122 (48%) patients in the non-resection group had ECOG PS \>1 compared with 79 (25%) patients in the resection group (p\<0.001). In addition, significant differences were noted between the two groups in relationship with serum creatinine, CEA and bilirubin.

Systemic therapy
----------------

Overall 326 (57%) patients received chemotherapy, 199 (64%) in the resection group and 127 (50%) in the non-resection group (p=0.001). Of 326 patients, 298 (91%) received either FOLFIRI (infusional 5 fluorouracil, leucovorin and irinotecan) or FOLFOX (infusional 5 fluorouracil, leucovorin and oxaliplatin), 157 (48%) received both FOLFIRI and FOLFOX, 213 (65%) received bevacizumab, and 34 (10%) patients with KRAS wild tumor (about 60% had KRAS wild disease) received cetuximab or panitumumab. Of 326 patients who were treated with chemotherapy, on progression 174 (53%) received second line chemotherapy and 52 (16%) received third line therapy. FOLFIRI in combination with bevacizumab was the preferred first line regimen in most patients who were treated with systemic therapy. On progression, FOLFOX was given as second line therapy and panitumumab or cetuximab alone or in combination with irinotecan was used as the standard third line therapy in patients with KRAS wild tumor. There was no significant difference between the two groups in relation to second and third line therapies (**Table [1](#T1){ref-type="table"}**). Furthermore, no significant difference was noted between the two groups with respect to types of systemic therapy, however, 45% patients in the resection group who were treated with systemic therapy received all available therapy (FOLFIRI, FOLFOX and a biologic agent) compared with 35% patients in the non-resection group (p=0.045). Of 199 patients in the resection group who received chemotherapy, 172 (86%) received chemotherapy after surgery. The median time to start chemotherapy was 79 days (IQR: 64-106).

Disease Characteristics
-----------------------

Overall about 41% patients in the non-resection group had rectal or rectosigmoid primary tumor compared with 28% in the resection group (p=0.001). In addition, approximately 54% patients in the non-resection group had stage IVb disease compared with 40% in the resection group (p=0.001). Patients in the resection group had significantly more often peritoneal disease compared with patients in the non-resection group who had more often lung or bone metastases.

Post-operative morbidities and mortality
----------------------------------------

Median duration of hospital stay of was 9 days (inter-quartile range: 7-13). Of 313 patients who underwent surgery 74 (24%) patients developed post-operative complications. Among 74 patients who developed operative complications 65% had a symptomatic primary tumor. Post-operative complications rates were not mutually exclusive and were as followed: post-operative wound infection in 7% patients, non-wound infection in 5% patients, and anastomotic leak, wound dehiscence, bleeding, and pulmonary embolism in 2% each. Major complications including venous thromboembolism, sepsis, wound dehiscence, anastomotic leakage, post-operative bleeding, pelvic abscess and ischemic bowel were noted in 37 (12%) patients. Of note, 10 (7%) of 142 patients with asymptomatic or minimally symptomatic tumor developed major complications compared with 27 (16%) of 171 patients with symptomatic primary tumor (p=0.01).

Overall 30 days mortality rate of the group who underwent surgery was 5%. Fifteen of 171 (9%) patients with symptomatic disease compared with 2 (1%) of 142 patients with asymptomatic or minimally symptomatic disease died within 30 days of surgery (p=0.003).

Non-Surgical Interventions
--------------------------

Overall 30 (5%) patients required a stent for their symptoms. Eight (3%) of 313 patients who underwent surgery compared with 22 (9%) of 256 patients who did not have surgery required a stent (p=0.001). All 8 patients in the surgery group had the stent placed prior to the surgery. In addition, 38 (15%) patients in the non-resection group developed obstructive symptoms and required a stoma formation (colostomy or ileostomy). Forty-five (14%) patients in the resection group compared with 45 (17.6) of 256 patients in the non-resection group received radiation therapy (p=0.30).

Follow up & Survival
--------------------

Median follow up time for the entire cohort was 11 months (inter-quartile range: 2-26 months). No patient was lost to follow up. Median overall survival (OS) of patients who underwent removal of the primary tumor, irrespective of the use of systemic therapy, was 18 months (95% CI: 15.4-20.6) compared with 4 months (95% CI: 2.6-5.4) if they did not have surgery (p\<0.001). Median overall survival (OS) of patients who underwent SRPT and received chemotherapy was 27 months (95%CI: 23.3-30.8) versus 14 months (95%CI: 11.2-16.8) if they received chemotherapy but did not have surgery (p\<0.001) \[**Figure [2](#F2){ref-type="fig"}**\]. Patients who received second line therapy and underwent SRPT had median OS of 30 months (95%CI: 24.9-35.1) compared with 20 months (95%CI: 17.7-22.3) if they did not have surgery (p\<0.001) \[**Figures [3](#F3){ref-type="fig"}A & 3B**\]. About 30% patients on progression received third line therapy. The median OS of patients who received third line therapy and underwent SRPT was 39 months (95%CI: 22.1-44.9) compared with 26 months (95%CI: 10.3-41.7) if they did not have surgery (p=0.13). Median OS of patients who received FOLFIRI and FOLFOX and a biologic agent (bevacizumab or anti-EGFR monoclonal antibodies) and underwent SRPT was 35 months (95% CI: 30-40) compared with 23 months (95%CI: 19.8-26.3) if they did not surgery (p\<0.001) \[**Figure [4](#F4){ref-type="fig"}**\]. A subgroup of patients with asymptomatic or minimally symptomatic primary tumor who underwent surgery and received systemic therapy had a median OS of 34 months (95%CI: 26.6-43.4) compared with median OS of 14 months (95%CI: 11.1-17.0) if they did not have surgery (p\<0.001).

Cox Proportional multivariate modeling for survival
---------------------------------------------------

One univariate analyses several variables were correlated with survival (**Table [2](#T2){ref-type="table"}**). Tests for interaction were significant between resection of primary tumor and metastasectomy, second line therapy, stage IVb disease and elevated BUN. On multivariate analysis SRPT independently correlated with superior survival with HR for mortality of 0.44 (95%CI: 0.35-0.56). In addition, chemotherapy, HR 0.33 (95%CI: 0.26-0.43), metastasectomy, HR 0.43 (95%CI: 0.31-0.58), second line therapy, HR 0.50 (95%CI:0.35-0.70), and third line therapy, HR 0.58 (95%CI:0.41-0.83) were correlated with superior survival whereas elevated alkaline phosphatase, HR 1.50 (95%CI:1.20-1.78), grade 3 tumor, HR 1.33 (95%CI:1.10-1.62), leukocytosis, HR 1.32 (95%CI:1.05-1.66), stage IVb disease, HR 1.31 (95%CI:1.10-1.56), and ECOG PS \>1, HR 1.30 (95%CI:1.04-1.57) were correlated with inferior survival (**Table [3](#T3){ref-type="table"}**).

After adjustment for other prognostic variables only the interaction between SRPT and subsequent line of therapy was significant suggesting a differential benefit of removal of primary tumor in patients who received other line of therapies. Patients who underwent SRPT and received second line therapy had a median OS of 30 months (95%CI:24.9-35.1) compared with 20 months (95%CI:17.7-22.3) if they did not have surgery (p \<0.001). Conversely, patients who had SRPT but did not receive second line therapy had a median OS of 19 months (95% CI: 11.8-26.2) compared with 7 months (95%CI: 5.4-8.6) if they did not have surgery (P\<0.001).

Secondary analyses
------------------

In the secondary multivariate analyses that excluded the patients who underwent metastasectmy, SRPT was independently associated with significant reduction in mortality with HR, 0.48 (95%CI: 0.38-0.61). Likewise, in a subgroup of 345 patients with asymptomatic or relatively asymptomatic primary tumors, SRPT was significantly correlated with better survival with HR 0.32 (95%CI: 0.22-0.45). Similar benefits were noted in sub-cohorts of patients with colon cancer or ECOG performance status of 0 or 1. In the subgroup of 379 patients with colon cancer surgery independently correlated with survival with HR for mortality of 0.39 (95% CI: 0.29-0.53). After excluding patients with poor performance status resection of the primary tumor remained an independent prognostic variable with HR of 0.48 (95%CI: 0.35-0.66).

Discussion
==========

The present study confirmed the survival benefit of SRPT in patients who were treated with combination chemotherapy and biologics. In addition to surgery of the primary tumor, systemic therapy, subsequent line of therapies, metastasectomy, elevated alkaline phosphatase, grade 3 tumor, leukocytosis, stage IVb disease, and performance status were correlated with survival. A significantly higher proportion of patients in the non-resection group had low performance status or larger number of metastatic sites involvement. Furthermore, there was imbalance between the two groups in relation to combination therapy and biologics. Nonetheless, when these variables were included in a multivariate model, SRPT remained an important independent prognostic factor. In fact, the survival benefit was stronger than the other well-established prognostic factors in stage IV CRC including performance status, alkaline phosphatase levels, and the number of metastatic sites [@B8],[@B9].

The median overall survival of patients with stage IV cancer, who are treated with combination of chemotherapy and biologics in the recent phase 3 clinical trials, has been reported in the range of 24-30 months [@B10]-[@B12]. However, our cohort was comprised of real world patients and was inclusive of patients with poor performance status and major comorbid illness. Although the median overall survival of the entire cohort was 11 months (8.8-13.2), the survival of patients who underwent SRPT and received chemotherapy was 27 months (95%CI: 23.3-30.8). Moreover, patients who underwent SRPT and received second and third line therapy had median OS of 30 months (95%CI: 24.9-35.1) and 39 months (95%CI: 22.1-44.9), respectively.

Recent literature also supports survival benefit of SRPT in the era of modern chemotherapy. A retrospective analysis of CAIRO study that compared combination versus sequential chemotherapy demonstrated a significantly better median OS of 16.7 months in patients who underwent SRPT compared with 11.4 months with no surgery (HR 0.61, 95%CI:49-0.76) \[6\]. Likewise, a pool analysis of four French phase 3 trials involving 850 patients indicated survival benefit of surgery [@B4]. More than two third of patients were treated with FOLFIRI or FOLFOX and about 12% received bevacizumab. The primary tumor resection was an independent predictor of superior survival (HR: 0.63, 95%CI: 0.53-0.75). In addition our group\' meta-analysis of fifteen observational studies did not reveal a positive interaction between surgery and type of chemotherapy.

In agreement with previous observation, patients with asymptomatic or minimally symptomatic disease following surgery had longer survival compared with patients with symptomatic primary tumor [@B13]. Of note patients with symptomatic primary tumor had 30 days post-operative mortality rates of 8.8% compared 1.5 % if they had an elective surgery. Emergency surgery has consistently been demonstrated to be an important risk factor for inferior outcome in colorectal surgery [@B14]. We believe that in addition to the biology of symptomatic disease, the 30 days mortality rates most likely accounted for the differences in survival between the two groups. In consistent with our previous observation, significantly higher number of patients with colon tumor underwent surgery compared with patients with rectal cancer. However, compared with 12992-2005 cohort, patients with rectal cancer did not have better prognosis.

Among the prognostic factors, systemic therapy was the most important prognostic variables. It is known that survival of patients with stage IV CRC is better if they are exposed to all available active therapeutic agents during the course of their disease [@B15]. The subgroup of patients who received combination chemotherapy with bevacizumab and underwent SRPT had median survival of 35 months (95% CI: 30-40) whereas patients with KRAS wild tumor who received FOLFIRI & FOLFOX in combination with bevacizumab and subsequently were treated with an anti-EGFR monoclonal antibody had a median OS of 39 months (95%CI: 25.1-52.9).

Due to presence of multicollinearity between various lines of chemotherapy and the type of regimens, these variables were not fitted together in the final model. A secondary analysis using chemotherapy regimens and biological agents as opposed to the subsequent lines of therapies was performed (not reported). Both combination of chemotherapy (HR: 0.67, 95%CI: 0.52-0.87) and biological agents (HR:0.60, 95%CI:0.45-0.78) were independently correlated with superior survival. Of significant importance, when various chemotherapy regimens were fitted in the multivariate model, resection of primary tumor was independently correlated with survival.

Our study revealed positive interaction between SRPT and second line therapy. The patients who had surgery and received second line therapy had a median OS of 30 months compared with 19 months if they did not receive second line therapy (p=0.005). With access to novel agents and their efficacy in the primary tumor as well as lack of major complications related to an intact primary tumor, SRPT is less commonly performed [@B16]-[@B18]. Our results, however, support potential benefit of surgery in patients who are treated with modern chemotherapy and suggest a greater benefit in patients who are treated with subsequent line of therapy. Our study is unique that it included performance status, an important prognostic variables in metastatic CRC, in the multivariate model. Most population based studies that support benefit of surgery lack individual patients\' data and have failed to include performance status in the multivariate models.

In summary the current study suggests survival benefit of SRPT in patients with advanced CRC. To date, no randomized trial has reported survival impact of SRPT in stage IV CRC. Only a prospective randomized trial could confirm the survival benefit conferred by the primary tumor resection. Such trials are ongoing in Europe and will be important to solve this very important question in the management of stage IV CRC.

The study was supported by a research grant from Saskatchewan Cancer Agency. We would like to thanks to Dr. Bonnie Janzen, Mrs. Carla Woites, Dr. Tong Zhu, and Saskatchewan Cancer Agency for their support for this project.

Part of the data was presented at 2015 Gastrointestinal Cancers Symposium, San Francisco, CA, USA.
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Overall survival of patients who received second line therapy and underwent surgery of the primary tumor (2A) versus if they did not receive second line therapy (3B).
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###### 

Characteristics of patients in the entire cohort and subgroups of patients who were treated with surgery and systemic therapy versus systemic therapy alone.

  Variables                           Study cohort N=569   Resection group N=313 (55)   Non-resection group N=256 (45)   P value
  ----------------------------------- -------------------- ---------------------------- -------------------------------- ---------
  Demographic                                                                                                            
  Median age                          69 (30-95)           68 (33-95)                   70 (30-95)                       0.23
  Age 65 years or greater             340 (60)             180 (58)                     160 (62)                         0.23
  Previous History of Cancer          82 (14)              39 (13)                      43 (17)                          0.15
  ECOG performance status 2 or more   201 (35)             79 (25)                      122 (48)                         \<0.001
  Charlson comorbidity index \*       141 (25)             85 (27)                      56 (22)                          0.056
  Male                                335 (59)             181 (58)                     154 (60)                         0.61
  Current or ex-smoker                344 (60)             196 (63)                     148 (58)                         0.26
  Laboratory values                                                                                                      
  Albumin g/l                         32 ±6                33 ±7                        31 ±6                            0.39
  Alkaline phosphatase U/l            202 ±277             179 ±309                     230 ±229                         0.12
  Bilirubin ug/l                      15 ±24               11 ±11                       18 ±34                           \<0.001
  Blood urea nitrogen mm/l            7 ±27                7 ±29                        8 ±24                            0.86
  CEA ug/l                            581 ±3006            376 ±1988                    830 ±3895                        0.004
  Creatinine um/l                     91 ±63               86 ±31                       97 ±88                           \<0.001
  Hemoglobin g/l                      111 ±119             123 ±16                      118 ±17                          0.82
  Platelet 10^9^/l                    350 ±124             334 ±114                     368 ±135                         0.061
  White blood cell count 10^9^/l      11.3 ±47             8.9 ±8                       10.2 ±4                          0.61
  Sodium meq/l                        137 ±3               138 ±3                       137 ±3                           0.27
  Treatment                                                                                                              
  Chemotherapy                        326 (57)             199 (64)                     127 (50)                         0.001
  Second line therapy                 174 (53)             110 (55)                     64 (50)                          0.23
  Third line therapy                  52 (16)              36 (18)                      16 (13)                          0.12
  FOLFIRI OR FOLFOX                   298 (91)             182 (92)                     116 (91)                         0.56
  Biologics                           218 (67)             137 (69)                     81 (64)                          0.24
  FOLFIRI & FOLFOX plus a biologics   133 (41)             89 (45)                      44 (35)                          0.045
  Radiation therapy                   90 (16)              45 (14)                      45 (18)                          0.30
  Metastasectomy                      89 (16)              81 (26)                      8 (3)                            \<0.001
  Metastatic sites                                                                                                       
  Extra-hepatic disease               305 (54)             151 (48)                     154 (60)                         0.005
  Bone                                21 (7)               6 (4)                        15 (10)                          0.038
  Brain                               5 (2)                2 (1)                        3 (2)                            0.50
  Lung                                125 (41)             50 (33)                      75 (49)                          0.004
  Peritoneum                          124 (41)             73 (48)                      51 (33)                          0.005
  Tumor                                                                                                                  
  Stage IVb                           264 (46)             126 (40)                     138 (54)                         0.001
  Grade 3                             151 (27)             79 (25)                      72 (28)                          0.44
  Mucinous                            55 (10)              39 (13)                      16 (6)                           0.015
  Rectum or rectosigmoid tumor        190 (33)             86 (28)                      104 (41)                         0.001
  Symptomatic primary tumor           224 (39)             171 (55)                     53 (21)                          \<0.001

\*Mean Chalrson comorbidity score 9.58±1.53 in resection group compared with 9.50±1.44 non-resection group. Biologics= cetuximab, panitumumab or bevacizumab; CEA= carcinoembryonic antigen; ECOG= Eastern Cooporative Oncology Group; FOLFIRI=Infusional 5-FU, leucovorin and irinotecan; FOLFOX=Infusional 5-FU, leucovorin and oxaliplatin.

###### 

Relationship between various clinic-pathological variables and survival in univariate analysis.

  Variables                        HR (95% CI)        P value   HR (95% CI) for Interaction with SPRT   P value
  -------------------------------- ------------------ --------- --------------------------------------- ---------
  Age ≥65 years                    1.87 (1.56-2.25)   \<0.001   1.36 (0.95-1.94)                        0.096
  Male gender                      0.90 (0.75-1.10)   0.22      1.17 (0.83-1.67)                        0.37
  ECOG PS                          2.51 (2.09-3.02)   \<0.001   0.94 (0.65-1.36)                        0.75
  Comorbid illness                 1.50 (1.23-1.85)   \<0.001   1.11 (0.74-1.67)                        0.63
  Current Smoking                  0.86 (0.69-1.08)   0.20      0.80 (0.52-1.26)                        0.35
  Ex-Smoking                       0.91 (0.76-1.09)   0.31      1 (0.70-1.43)                           0.98
  Treatment Centers                1.04 (0.87-1.23)   0.68      1.33 (0.94-1.89)                        0.11
  Albumin \<35 g/l                 1.95 (1.60-2.39)   \<0.001   0.76 (0.49-1.19)                        0.23
  Alkaline phosphatase \>120 U/l   2.17 (1.79-2.62)   \<0.001   1.04 (0.70-1.55)                        0.85
  Bilirubin ≥26 um/l               1.77 (1.28-2.46)   0.001     1.93 (0.97-3.87                         0.06
  BUN ≥8 mm/l                      1.48 (1.13-1.93)   0.007     1.82 (1.05-3.16)                        0.034
  CEA ≥5 ug/l                      2.11 (1.63-2.76)   \<0.001   1.18 (0.64-2.20)                        0.60
  Creatinine ≥120 um/l             1.46 (1.06-1.99)   0.026     1.36 (0.72-2.57)                        0.34
  Hemoglobin \<120 g/l             1.82 (1.49-2.22)   \<0.001   0.90 (0.60-1.34)                        0.60
  Platelet count, ≥450 x10^9^/l    0.92 (0.73-1.17)   0.51      1.14 (0.70-1.86)                        0.60
  WBC ≥11 x 10^9^/l                1.39 (1.12-1.71)   0.004     1.30 (0.84-2.01)                        0.23
  Sodium \<135 meq/l               1.19 (0.95-1.48)   0.14      1.02 (0.65-1.60)                        0.92
  Extra-hepatic disease            1.21 (1.02-1.44)   0.031     1.36 (0.96-1.94)                        0.08
  Grade 3                          1.48 (1.22-1.79)   \<0.001   1.34 (0.91-1.97)                        0.14
  Mucinous pathology               1.13 (0.85-1.51)   0.40      1.74 (0.92-3.28)                        0.09
  Rectum                           0.80 (0.66-0.96)   0.014     0.84 (0.58-1.24)                        0.39
  Stage IVb disease                1.38 (1.16-1.64)   \<0.001   1.43 (1.01-2.03)                        0.04
  Symptomatic primary tumor        1.08 (0.90-1.28)   0.42      1.05 (0.71-1.55)                        0.82
  Primary tumor resection          0.44 (0.37-0.53)   \<0.001   NA                                      NA
  Metastasectomy                   0.30 (0.22-0.40)   \<0.001   0.74 (0.58-0.94)                        0.015
  Chemotherapy                     0.24 (0.20-0.29)   \<0.001   1.36 (0.95-1.94)                        0.09
  Second line Treatment            0.44 (0.36-0.53)   0.025     2.10 (1.28-3.35)                        0.003
  Third line Treatment             0.41 (0.30-0.56)   \<0.001   1.77 (0.89-3.49)                        0.10
  FOLFOX or FOLFIRI                0.27 (0.23-0.33)   \<0.001   1.49 (1.04-2.12)                        0.029
  Biologics                        0.34 (0.28-0.41)   \<0.001   1.44 (1.0-2.08)                         0.05
  Radiation                        0.66 (0.52-0.84)   \<0.001   0.97 (0.60-1.57)                        0.90

Biologics= cetuximab, panitumumab or bevacizumab; CEA= carcinoembryonic antigen; ECOG PS= Eastern Cooporative Oncology Group performance status; FOLFIRI=Infusional 5-FU, leucovorin and irinotecan; FOLFOX=Infusional 5-FU, leucovorin and oxaliplatin.

###### 

Relationship between various clinic-pathological variables and survival in multivariate analysis.

  Variables                             HR (95% CI)
  ------------------------------------- ------------------
  Surgical resection of primary tumor   
  Yes                                   0.44 (0.35-0.56)
  No                                    1
  Chemotherapy                          
  Yes                                   0.33 (0.26-0.43)
  No                                    1
  Second line therapy                   
  Yes                                   0.50 (0.35-0.70)
  No                                    1
  Third line therapy                    
  Yes                                   0.58 (0.41-0.83)
  No                                    1
  Alkaline phosphatase \>120 U/l        
  Yes                                   1.50 (1.20-1.78)
  No                                    1
  Grade 3 tumors                        
  Yes                                   1.33 (1.10-1.62)
  No                                    1
  Leukocytosis                          
  Yes                                   1.32 (1.05-1.66)
  No                                    1
  Stage IVb disease                     
  Yes                                   1.31 (1.10-1.56)
  No                                    
  ECOG performance status \>1           
  Yes                                   1.30 (1.04-1.57)
  No                                    1
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